The ASCOMALVA (Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease) Trial: Interim results after two years of treatment

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S281-S288

  Amenta, Francesco ^a   Carotenuto, Anna ^a   Fasanaro, Angiola Maria ^b   Rea, Raffaele ^a   Traini, Enea ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; association; cerebrovascular injury; choline alphoscerate; donepezil

Indexed keywords

CHOLINE ALFOSCERATE; DONEPEZIL; PLACEBO; GLYCEROPHOSPHORYLCHOLINE; INDAN DERIVATIVE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE;

ACETYLCHOLINE BRAIN LEVEL; ADULT; AGED; ALZHEIMER DISEASE; ASTHENIA; BEHAVIOR; BRAIN DAMAGE; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HALLUCINATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUROIMAGING; OBSERVATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REFERENCE VALUE; TREATMENT DURATION; TREATMENT PLANNING; VERY ELDERLY; VOMITING; ANALYSIS OF VARIANCE; CLINICAL TRIAL; LONGITUDINAL STUDY; MENTAL HEALTH; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLYCERYLPHOSPHORYLCHOLINE; HUMANS; INDANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PIPERIDINES; SEVERITY OF ILLNESS INDEX;

EID: 84920588383     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140150     Document Type: Conference Paper

References (27)

1. Giacobini E (1998) Cholinergic foundations of Alzheimer's disease therapy. J Physiol Paris 92, 283-287.
2. Amenta F, Parnetti L, Gallai V, Wallin A (2001) Treatment of cholinergic dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech Ageing Dev 122, 2025-2040.
3. Gauthier S (2002) Advances in the pharmacotherapy of Alzheimer's disease. CMAJ 166, 616-623.
4. Brashear HR (2003) Galantamine in the treatment of vascular dementia. Int Psychogeriatr 15, 187-193.
5. Roman GC (2003) Vascular dementia: Distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 51, S296-S304.
6. Jones RW (2003) Have cholinergic therapies reached their clinical boundary in Alzheimer's disease? Int J Geriatr Psychiatry 18, S7-S13.
7. Higgins JP, Flicker L (2003) Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev, CD001015.
8. Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F (2007) Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for reevaluation? J Neurol Sci 257, 264-269.
9. Traini E, Bramanti V, Amenta F (2013) Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old cholinecontaining phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res 10, 1070-1079.
10. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H (2005) Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomised clinical trials. BMJ 331, 321-327.
11. Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1, CD005593.
12. Birks J, Harvey R (2006) Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 1, CD001190.
13. Amenta F, Tayebati SK, Vitali D, Di Tullio MA (2006) Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: An approach for enhancing cholinergic neurotransmission. Mech Ageing Dev 127, 173-179.
14. Tayebati SK, Di Tullio MA, Tomassoni D, Amenta F (2009) Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats. J Neurol Sci 283, 187-194.
15. Everitt BJ, Robbins TW (1997) Central cholinergic systems and cognition. Annu Rev Psychol 48, 649-684.
16. Kiewert C, Mdzinarishvili A, Hartmann J, Bickel U, Klein J (2010) Metabolic and transmitter changes in core and penumbra after middle cerebral artery occlusion in mice. Brain Res 1312, 101-107.
17. Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E (2012) The ASCOMALVA trial: Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: Interim results. J Neurol Sci 322, 96-101.
18. Auld DS, Kornecook TJ, Bastianetto S, Quinron R (2002) Alzheimer's disease and the basal forebrain cholinergic system: Relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68, 209-245.
19. Schliebs R, Arendt T (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 113, 1625-1644.
20. Francis PT, Ramrez MJ, Lai MK (2010) Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 59, 221-229.
21. (2011) Syncope with cholinesterase inhibitors. Prescrire Int 20, 240.
22. (2011) Bradycardia due to cholinesterase inhibitors: Identify adverse effects and take them into account. Prescrire Int 20, 95.
23. Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia:Ameta-analysis of randomised controlled trials. Lancet Neurol 6, 782-792.
24. Parnetti L, Amenta F, Gallai V (2001) Choline alphoscerate in cognitive decline and in acute cerebrovascular disease. An analysis of published clinical data. Mech Ageing Dev 122, 2041-2055.
25. Tomimoto H (2012) Vascular cognitive impairment: The relationship between hypertensive small vessel disease and cerebral amyloid angiopathy. Brain Nerve 64, 1377-1386.
26. De Reuck JL (2012) The significance of small cerebral bleeds in neurodegenerative dementia syndromes. Aging Dis 3, 307-312.
27. De Reuck J, Deramecourt V, Cordonnier C, Leys D, Maurage CA, Pasquier F (2011) The impact of cerebral amyloid angiopathy on the occurrence of cerebrovascular lesions in demented patients with Alzheimer features: A neuropathological study. Eur J Neurol 18, 913-918.